166 related articles for article (PubMed ID: 19516269)
1. Ceragenins: a class of antiviral compounds to treat orthopox infections.
Howell MD; Streib JE; Kim BE; Lesley LJ; Dunlap AP; Geng D; Feng Y; Savage PB; Leung DY
J Invest Dermatol; 2009 Nov; 129(11):2668-75. PubMed ID: 19516269
[TBL] [Abstract][Full Text] [Related]
2. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances.
Smee DF; Bailey KW; Wong MH; Tarbet EB
Antivir Chem Chemother; 2011 May; 21(5):201-8. PubMed ID: 21566266
[TBL] [Abstract][Full Text] [Related]
3. Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes.
MacLeod DT; Nakatsuji T; Wang Z; di Nardo A; Gallo RL
J Invest Dermatol; 2015 Jan; 135(1):142-150. PubMed ID: 25089661
[TBL] [Abstract][Full Text] [Related]
4. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus.
Howell MD; Gallo RL; Boguniewicz M; Jones JF; Wong C; Streib JE; Leung DY
Immunity; 2006 Mar; 24(3):341-8. PubMed ID: 16546102
[TBL] [Abstract][Full Text] [Related]
5. Treatment of poxvirus infections in rabbits with 9-beta-D-arabinofuranosyladenine.
Klein RJ; Friedman-Kien AE; Brady E
Antimicrob Agents Chemother; 1974 Apr; 5(4):409-12. PubMed ID: 15825397
[TBL] [Abstract][Full Text] [Related]
6. Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus.
Kim BE; Leung DY; Streib JE; Kisich K; Boguniewicz M; Hamid QA; Howell MD
J Allergy Clin Immunol; 2007 Feb; 119(2):457-63. PubMed ID: 17141855
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.
Tarbet EB; Larson D; Anderson BJ; Bailey KW; Wong MH; Smee DF
Antiviral Res; 2011 Jun; 90(3):126-33. PubMed ID: 21439326
[TBL] [Abstract][Full Text] [Related]
8. Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation.
Scott JE; ElKhal A; Freyschmidt EJ; MacArthur DH; McDonald D; Howell MD; Leung DY; Laouar A; Manjunath N; Bianchi T; Boes M; Oettgen HC; Geha RS
J Allergy Clin Immunol; 2007 Dec; 120(6):1382-8. PubMed ID: 17889291
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.
Quenelle DC; Collins DJ; Kern ER
Antimicrob Agents Chemother; 2003 Oct; 47(10):3275-80. PubMed ID: 14506041
[TBL] [Abstract][Full Text] [Related]
10. Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides.
Wang Z; Lai Y; Bernard JJ; Macleod DT; Cogen AL; Moss B; Di Nardo A
J Immunol; 2012 Jan; 188(1):345-57. PubMed ID: 22140255
[TBL] [Abstract][Full Text] [Related]
11. Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses.
Freyschmidt EJ; Mathias CB; Diaz N; MacArthur DH; Laouar A; Manjunath N; Hofer MD; Wurbel MA; Campbell JJ; Chatila TA; Oettgen HC
J Immunol; 2010 Jul; 185(2):1295-302. PubMed ID: 20548030
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of S100A11 gene expression impairs keratinocyte response against vaccinia virus through downregulation of the IL-10 receptor 2 chain.
Bin L; Howell MD; Kim BE; Hall CF; Streib JE; Leung DY
J Allergy Clin Immunol; 2009 Aug; 124(2):270-7, 277.e1. PubMed ID: 19577285
[TBL] [Abstract][Full Text] [Related]
13. Skin inflammation in RelB(-/-) mice leads to defective immunity and impaired clearance of vaccinia virus.
Freyschmidt EJ; Mathias CB; MacArthur DH; Laouar A; Narasimhaswamy M; Weih F; Oettgen HC
J Allergy Clin Immunol; 2007 Mar; 119(3):671-9. PubMed ID: 17336617
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice.
Neyts J; De Clercq E
J Med Virol; 1993 Nov; 41(3):242-6. PubMed ID: 8263505
[TBL] [Abstract][Full Text] [Related]
15. Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin.
Fisher RW; Reed JL; Snoy PJ; Mikolajczyk MG; Bray M; Scott DE; Kennedy MC
Clin Vaccine Immunol; 2011 Jan; 18(1):67-74. PubMed ID: 21106779
[TBL] [Abstract][Full Text] [Related]
16. The role for host-immune factors in the in vivo antiviral effects of tumour necrosis factor.
Lidbury BA; Ramshaw IA; Sambhi SK
Cytokine; 1995 Feb; 7(2):157-64. PubMed ID: 7780035
[TBL] [Abstract][Full Text] [Related]
17. Vaccinia virus pathogenicity in atopic dermatitis is caused by allergen-induced immune response that prevents the antiviral cellular and humoral immunity.
Becker Y
Virus Genes; 2003 Dec; 27(3):269-82. PubMed ID: 14618088
[TBL] [Abstract][Full Text] [Related]
18. Specificity protein 1 is pivotal in the skin's antiviral response.
Bin L; Howell MD; Kim BE; Streib JE; Hall CF; Leung DY
J Allergy Clin Immunol; 2011 Feb; 127(2):430-438.e1-2. PubMed ID: 21208652
[TBL] [Abstract][Full Text] [Related]
19. Vaccinia virus induces rapid necrosis in keratinocytes by a STAT3-dependent mechanism.
He Y; Fisher R; Chowdhury S; Sultana I; Pereira CP; Bray M; Reed JL
PLoS One; 2014; 9(11):e113690. PubMed ID: 25419841
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.
McCausland MM; Benhnia MR; Crickard L; Laudenslager J; Granger SW; Tahara T; Kubo R; Koriazova L; Kato S; Crotty S
Antivir Ther; 2010; 15(4):661-75. PubMed ID: 20587859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
